MIV Therapeutics Names Harvard Interventional Cardiologist Dr. Joseph Carrozza to Scientific Advisory Board; Industry Authority to Help Guide Development of MIVT's Unique Coatings for Highly Biocompatible Cardiovascular Stents.

ATLANTA -- MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that Joseph P. Carrozza, Jr., M.D., Chief of Interventional Cardiology at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School, a widely recognized expert in the field of interventional cardiology, has joined the Company's Scientific Advisory Board.

As a member of the Scientific Advisory Board, Dr. Carrozza will help guide MIVT's research and development programs as the Company moves its proprietary technologies from the laboratory to the marketplace.

Dr. Carrozza is a leading authority in the field of interventional cardiology and has co-authored more than 100 papers relating to the treatment of cardiovascular disorders including initial descriptions of the link between diabetes mellitus and restenosis after stenting, stent recoil, and the no-reflow phenomenon after percutaneous coronary intervention. He has served as the Chief of the Section of Interventional Cardiology at Beth Israel Deaconess Medical Center in Boston for the past six years and is Associate Professor of Medicine at Harvard Medical School. Beth Israel Deaconess Medical Center is a Harvard Medical School teaching hospital.

"We are very pleased to welcome Dr. Carrozza as a strong addition to our Scientific Advisory Board," said Dr. Mark Landy, President of MIVT. "As we approach our First In Man clinical trials we look forward to the guidance and perspective that leading scientists like Dr. Carrozza can provide."

Prior to his work at Harvard, Dr. Carrozza was the Director of Interventional Animal Research at Beth Israel Hospital. He has also served as National Principal Investigator for four multi-center clinical trials and site Principal Investigator for more than 75 trials investigating a wide variety of devices and drugs for the treatment of coronary artery, valvular, and congenital heart diseases.

Dr. Carrozza's expertise will benefit MIVT's HAp-based biocompatible coating development, which is focused on substantially improving the safety and long-term performance of vascular stents and other devices.

The role of the Scientific Advisory Board is to review and advise the Company's management and Board of Directors on scientific strategies and procedures and to provide input and critique on the Company's Research and Development activities.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogycapital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.